Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia, with the highest incidence in the White, non-Hispanic population. To better understand underrepresented minority CLL patients, patients diagnosed with CLL from 2004-2018 were identified in the National Cancer Database. Of 97 804 CLL patients, 90.7% of patients were White, 7.6% Black. Compared to White patients, Black patients were younger (median age 66 years vs. 70 years), more likely to have ≥1 comorbidity (27.9% vs. 21.3%), more likely to receive CLL-directed therapy at diagnosis (35.9% vs 23.6%; p<0.001), and had a shorter median OS of 7.0 years (95% CI 6.7-7.3) compared to White patients (9.1 years [95% CI 9.0-9.3]), p<0.001). On multivariate analysis, Black race was independently associated with shorter OS (HR 1.51 [95% CI 1.46-1.57], p<0.001), which was also demonstrated in a propensity score matched sample (matched by age, comorbidity, and socioeconomic features), where Black patients had shorter OS compared to White patients (HR 1.30 [95% CI 1.23-1.37, p<0.001]). In the largest study to date describing minority CLL patients, we found significantly reduced survival in Black CLL patients, highlighting the need for targeted efforts to provide equitable outcomes.